News

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...
If you're one of the many people who have been interested in Ozempic-style weight loss medications but are terrified of ...
The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss ...
After reporting robust results, Resmed reckons it won't be subject to US tariffs while the growth of anti-obesity drugs will be a tailwind.
In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...
Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...
Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...